Polypharmacy for psychiatric treatments in Japan [10]

Lancet

Volumn 360, Issue 9333, 2002, Pages 647-

  Takei, Nori ^a   Inagaki, Ataru ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT; PHENOBARBITAL; PROMETHAZINE;

BIOACCUMULATION; DRUG BIOAVAILABILITY; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE POLICY; HUMAN; JAPAN; LETTER; MANAGEMENT; NEGATIVE SYNDROME; POLYPHARMACY; PRIORITY JOURNAL; PSYCHIATRY; QUALITY OF LIFE; REDUCTION; SCHIZOPHRENIA;

EID: 0037167238     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09803-3     Document Type: Letter

References (5)

1. Revicki D.A., Genduso L.A., Hamilton S.H., Ganoczy D., Beasley C.M. Jr. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: a quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 8:1999;417-426.
2. Meyer P.S., Bond G.R., Tunis S.L., McCoy M.L. Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program. J Clin Psychiatry. 63:2002;108-116.
3. Taylor D., McConnell H., Duncan-McConnell D., Kerwin R. 2001 prescribing guidelines. 6th edn: 2001;Martin Dunitz, London.
4. Inagaki A, Yoshizumi A, Oshima I, et al. JPSS-2 ni okeru yakubutsu ryouhou algorism ni tsuite. Presented at the Meeting of the "Heisei 13 Nendo Kenkyu Houkokukai", Dec 10, 2001, Tokyo.
5. Rittmannsberger H., Meise U., Schauflinger K., Horvath E., Donat H., Hinterhuber H. Polypharmacy in psychiatric treatment: patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry. 14:1999;33-40.